Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PAXIS: A Phase 2a and 2b Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome

NCT06782373 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT06782373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06782373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PAXIS: A Phase 2a and 2b Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 28, 2025
Completion date
May 22, 2030
Enrollment
156 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

vexas, vexas syndrome